Complex Commercial Litigation partner Jessica Falk was named a “Litigator of the Week” by The American Lawyer for her role in securing a complete, $400M+ plaintiff antitrust jury verdict for Regeneron Pharmaceuticals in Delaware federal court, a result that is sure to reverberate throughout the pharmaceutical industry.

After two weeks of trial and just one day of deliberation, the jury awarded more than $400M to Regeneron on its claims that competitor Amgen unlawfully monopolized the U.S. market for PCKSK9 inhibitors, a class of medications that reduce hard-to-treat high cholesterol. Regeneron invented and commercializes a lifesaving PCKSK9 inhibitor called Praluent®. This was a huge win for the client – the jury sided with Regeneron on 9 of its 10 claims – and its innovative treatments.

This outcome required collaboration among three different law firms representing Regeneron. It also required teamwork between Weil’s commercial trial lawyers and antitrust experts across offices. It was the result of years of intense litigation leading up to trial, and, as noted by The American Lawyer, it featured savvy lawyering by Weil’s associates.

The Weil trial and antitrust team was led by partner Jessica Falk, U.S. Antitrust Co-Head Michael Moiseyev, Appeals and Strategic Counseling Co-Head Robert Niles-Weed, and antitrust associate Rachel Williams. The Weil team also included associates Naz Akyol, Shai Berman, Katheryn Maldonado, Katya Dajani, Caroline Elvig, Matt Tonglet, and Grace Okoroafor, paralegals Camille George and Jonathan Mondschein, and trial graphics specialist Kim Wu.

Weil worked closely with White & Case and Orrick at trial. To read the full article, please click here.